## Ibrutinib treatment ameliorates murine chronic graft-v

Journal of Clinical Investigation 124, 4867-4876 DOI: 10.1172/jci75328

Citation Report

#	Article	IF	CITATIONS
1	Transplant for CLL: still an option?. Blood, 2014, 124, 3835-3836.	1.4	1
2	Graft-versus-host disease versus graft-versus-leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 225-230.	2.5	74
3	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	1.4	101
4	HY antibodies as biomarkers for chronic GVHD. Blood, 2015, 125, 3046-3047.	1.4	2
5	Syk and tired of current chronic GVHD therapies. Blood, 2015, 125, 3974-3975.	1.4	6
6	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights, 2015, 10s3, BMI.S22430.	2.5	29
7	Aberrant B-cell homeostasis in chronic GVHD. Blood, 2015, 125, 1703-1707.	1.4	107
8	The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse. Clinical Cancer Research, 2015, 21, 1981-1983.	7.0	2
9	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. International Journal of Hematology, 2015, 101, 438-451.	1.6	22
10	Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Science Translational Medicine, 2015, 7, 280rv2.	12.4	88
11	State-of-the-art acute and chronic GVHD treatment. International Journal of Hematology, 2015, 101, 452-466.	1.6	72
12	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 2016, 128, 2899-2908.	1.4	70
13	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	1.4	145
14	CLL: ibrutinib and transplantation ride together. Bone Marrow Transplantation, 2016, 51, 769-770.	2.4	1
15	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood, 2016, 127, 2249-2260.	1.4	74
16	Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?. Blood, 2016, 127, 3117-3126.	1.4	68
17	Augmentation of Recipient Adaptive Alloimmunity by Donor Passenger Lymphocytes within the Transplant. Cell Reports, 2016, 15, 1214-1227.	6.4	54
18	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host	2.0	11

	CITATION	CITATION REPORT	
#	ARTICLE Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic	IF	CITATIONS
19	lymphocytic leukemia. Therapeutic Advances in Hematology, 2016, 7, 231-232.	2.3	4
20	The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leukemia and Lymphoma, 2016, 57, 461-462.	1.3	1
21	Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 793-798.	2.4	25
22	Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 658-668.	2.0	23
23	Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research, 2016, 22, 1572-1582.	7.0	168
24	Emerging drugs for graft-versus-host disease. Expert Opinion on Emerging Drugs, 2016, 21, 209-218.	2.4	7
25	A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation. Bone Marrow Transplantation, 2016, 51, 410-417.	2.4	37
26	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22, 319-327.	7.0	68
27	A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2016, 22, 617-626.	2.0	19
28	Recovery of full donor chimerism with ibrutinib therapy in relapsed <scp>CLL</scp> after allogeneic stem cell transplantation. British Journal of Haematology, 2017, 176, 997-999.	2.5	5
29	Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia, 2017, 31, 177-185.	7.2	40
30	Role of B cells in the pathogenesis of systemic sclerosis. Revue De Medecine Interne, 2017, 38, 113-124.	1.0	37
31	Dermal and Subcutaneous Chronic Graft-Versus-Host Disease. , 2017, , 93-103.		0
32	Novel targets in the treatment of chronic graft-versus-host disease. Leukemia, 2017, 31, 543-554.	7.2	47
33	Precision monitoring of immunotherapies in solid organ and hematopoietic stem cell transplantation. Advanced Drug Delivery Reviews, 2017, 114, 272-284.	13.7	1
34	Longâ€ŧerm followâ€up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed Tâ€cell chimerism is associated with high relapse risk and inferior survival. British Journal of Haematology, 2017, 177, 567-577.	2.5	7
35	Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood, 2017, 129, 22-29.	1.4	98
36	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood, 2017, 129, 13-21.	1.4	216

#	Article	IF	CITATIONS
37	Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization. Transplant Immunology, 2017, 45, 59-64.	1.2	5
38	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nature Communications, 2017, 8, 978.	12.8	58
39	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood, 2017, 130, 2131-2145.	1.4	37
40	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 2017, 130, 2243-2250.	1.4	352
41	Cytokines in Hematopoietic Stem Cell Transplantation. , 2017, , 219-236.		1
42	Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. Clinics in Chest Medicine, 2017, 38, 575-593.	2.1	11
43	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood, 2017, 130, 2889-2899.	1.4	17
44	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328
45	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. New England Journal of Medicine, 2017, 377, 2565-2579.	27.0	469
46	The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. Biomedicines, 2017, 5, 61.	3.2	6
47	The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease. Expert Review of Clinical Immunology, 2018, 14, 389-404.	3.0	12
48	B-cell targeting in chronic graft-versus-host disease. Blood, 2018, 131, 1399-1405.	1.4	52
49	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discovery, 2018, 8, 458-477.	9.4	101
50	Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, S7-S14.	2.0	10
51	The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1125-1134.	2.0	73
52	Role of Bruton's tyrosine kinase in B cells and malignancies. Molecular Cancer, 2018, 17, 57.	19.2	435
53	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation. Inflammation, 2018, 41, 904-913.	3.8	13
54	Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. Bone Marrow Transplantation, 2018, 53, 1255-1262.	2.4	13

#	Article	IF	CITATIONS
55	Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment. American Journal of Clinical Dermatology, 2018, 19, 33-50.	6.7	112
56	Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clinical Infectious Diseases, 2018, 66, 140-148.	5.8	210
57	Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 19-26.	2.0	22
58	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. , 2018, , 1650-1668.e10.		1
59	Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treatment Reviews, 2018, 63, 116-121.	7.7	37
60	New and emerging therapies for acute and chronic graft <i>versus</i> host disease. Therapeutic Advances in Hematology, 2018, 9, 21-46.	2.5	90
61	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Journal of Clinical Oncology, 2018, 36, 2405-2412.	1.6	81
62	Modeling Chronic Graft Versus Host Disease in Mice Using Allogeneic Bone Marrow and Splenocyte Transfer. Current Protocols in Pharmacology, 2018, 83, e47.	4.0	5
63	Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. Blood, 2018, 132, 2188-2200.	1.4	30
64	How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Advances, 2018, 2, 2012-2019.	5.2	74
65	Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Advances, 2018, 2, 414-427.	5.2	18
66	Chronic graftâ€versusâ€host disease: Current management paradigm and future perspectives. Oral Diseases, 2019, 25, 931-948.	3.0	26
67	The use of ibrutinib before and after allogeneic stem cell transplantation. Expert Opinion on Orphan Drugs, 2019, 7, 171-180.	0.8	1
68	Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease—single center experience. Annals of Hematology, 2019, 98, 2399-2405.	1.8	5
69	B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice. Human Reproduction, 2019, 34, 1225-1234.	0.9	21
70	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2002-2007.	2.0	64
71	Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vsHost Disease. Frontiers in Immunology, 2019, 10, 2470.	4.8	15
72	Inpatient Management of Mucocutaneous GVHD. Current Dermatology Reports, 2019, 8, 258-278.	2.1	6

#	Article	IF	CITATIONS
73	Micro-RNA and Kinase Regulatory Mechanisms and Pathways in GVHD. , 2019, , 155-165.		1
74	T Cell– and B Cell–Mediated Pathology in Chronic Graft-Versus-Host Disease. , 2019, , 251-273.		Ο
75	Cytokines in GVHD and GVL. , 2019, , 293-322.		2
76	Summary and Outlook on the Future Challenges of Allogeneic HSCT. , 2019, , 415-422.		0
77	B cells in chronic graft-versus-host disease. Human Immunology, 2019, 80, 393-399.	2.4	46
78	Expansion of circulating extrafollicular helper T-like cells in patients with chronic graft-versus-host disease. Journal of Autoimmunity, 2019, 100, 95-104.	6.5	7
79	Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma. Drug Safety - Case Reports, 2019, 6, 3.	0.9	1
80	Targeting PI3Kl̂´function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
81	Cell-Based Medicine and Therapy. , 2019, , 237-252.		0
82	Developing role of B cells in the pathogenesis and treatment of chronic GVHD. British Journal of Haematology, 2019, 184, 323-336.	2.5	33
83	Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplantation, 2020, 55, 586-594.	2.4	19
84	T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cellular and Molecular Immunology, 2020, 17, 1042-1052.	10.5	40
85	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Blood Reviews, 2020, 40, 100635.	5.7	29
86	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplantation, 2020, 55, 884-890.	2.4	13
87	Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. Frontiers in Immunology, 2020, 11, 593863.	4.8	21
88	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 2020, 142, 2443-2455.	1.6	121
89	New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Frontiers in Immunology, 2020, 11, 578314.	4.8	55
90	Integrative Analysis of Long Noncoding RNAs in Patients with Graft-versus-Host Disease. Acta Haematologica, 2020, 143, 533-551.	1.4	7

#	Article	IF	CITATIONS
91	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nature Reviews Clinical Oncology, 2020, 17, 475-492.	27.6	80
92	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Annals of the American Thoracic Society, 2021, 18, 381-394.	3.2	26
93	Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 956-959.	2.4	8
94	Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease. International Journal of Molecular Sciences, 2021, 22, 2385.	4.1	5
95	Functional Contributions of Antigen Presenting Cells in Chronic Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 614183.	4.8	4
97	Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annual Review of Immunology, 2021, 39, 19-49.	21.8	79
98	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. Blood, 2021, 137, 2403-2416.	1.4	11
99	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCl9922). Melanoma Research, 2021, 31, 162-172.	1.2	6
100	BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. Blood, 2021, 137, 2544-2557.	1.4	23
101	Donor Treg expansion by liposomal αâ€galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graftâ€versusâ€host disease. Immunity, Inflammation and Disease, 2021, 9, 721-733.	2.7	3
102	Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells. ImmunoHorizons, 2021, 5, 424-437.	1.8	3
103	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. Molecules and Cells, 2021, 44, 408-421.	2.6	18
104	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. Journal of Clinical Investigation, 2021, 131, .	8.2	16
105	Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. Frontiers in Cell and Developmental Biology, 2021, 9, 668131.	3.7	26
106	Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. Current Pharmaceutical Design, 2022, 28, 437-444.	1.9	17
107	Experimental Models of Infectious Pulmonary Complications Following Hematopoietic Cell Transplantation. Frontiers in Immunology, 2021, 12, 718603.	4.8	2
108	Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives. Frontiers in Immunology, 2021, 12, 713358.	4.8	10
109	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. Immunotherapy, 2021, 13, 977-987.	2.0	3

		REPORT	
#	ARTICLE	IF	CITATIONS
110	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Ilb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
111	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplantation and Cellular Therapy, 2021, 27, 990.e1-990.e7.	1.2	16
112	An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 867.e1-867.e9.	1.2	11
113	The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. Frontiers in Pharmacology, 2020, 11, 625498.	3.5	4
114	Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation. Organ and Tissue Transplantation, 2021, , 395-419.	0.0	0
115	Evolving Therapeutic Options for Chronic Graftâ€versusâ€Host Disease. Pharmacotherapy, 2020, 40, 756-772.	2.6	11
117	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. JCI Insight, 2018, 3, .	5.0	24
118	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, .	5.0	53
119	Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation, 2017, 127, 3052-3064.	8.2	280
120	Cytokine mediators of chronic graft-versus-host disease. Journal of Clinical Investigation, 2017, 127, 2452-2463.	8.2	74
121	Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. PLoS ONE, 2015, 10, e0137641.	2.5	84
122	Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 2016, 11, e0167997.	2.5	2
123	T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor. Frontiers in Immunology, 2021, 12, 761448.	4.8	42
125	Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation. Organ and Tissue Transplantation, 2020, , 1-26.	0.0	0
126	Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database. Frontiers in Pharmacology, 2021, 12, 769315.	3.5	7
127	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. Journal of Experimental Pharmacology, 2021, Volume 13, 923-935.	3.2	11
128	Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD). Metabolites, 2021, 11, 736.	2.9	8
129	Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies Frontiers in Oncology, 2021, 11, 737943	2.8	13

		CITATION REPORT		
#	Article		IF	Citations
130	American Society of Hematology Annual Meeting and Exposition. P and T, 2017, 42, 1	35-139.	0.9	1
132	ITK inhibition promotes long-term survival of cardiac allografts by regulating T cell PLC phosphorylation. American Journal of Translational Research (discontinued), 2020, 12,	3 5762-5771.	0.0	1
134	Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease. Front Immunology, 2021, 12, 760199.	ers in	4.8	18
135	Mouse models of graft-versus-host disease. Methods in Cell Biology, 2022, 168, 41-66		1.1	1
136	Post-transplant GVHD in the era of molecularly targeted therapy. Journal of Illusion, 20	22, 11, 53-63.	0.1	0
137	Three US Food and Drug Administration–approved therapies for chronic GVHD. Bloc 1642-1645.	d, 2022, 139,	1.4	30
138	BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted ger distinct transcriptomes. Blood, 2022, 139, 2983-2997.	minal centers with	1.4	6
139	Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. Oncologist, 202	2, 27, 685-693.	3.7	23
151	Recent insights to the mechanisms of graft-versus-host disease. Rinsho Ketsueki/the Ja of Clinical Hematology, 2016, 57, 2169-2175.	panese Journal	0.5	0
154	Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Ch Lymphocytic Leukemia In Vivo. Cells, 2022, 11, 2325.	ronic	4.1	5
155	Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Pediatric Patients. Cureus, 2022, , .	Reported Use in	0.5	2
156	Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells and tissue-resident T-helper chronic GVHD. Blood, 2022, 140, 2740-2753.	er cells in	1.4	3
157	Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalize chronic GvHD. Blood Advances, 2023, 7, 4886-4902.	d treatment of	5.2	6
158	Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic mar Journal of the American Academy of Dermatology, 2024, 90, 19-36.	agement.	1.2	1
159	A first case of successful using of ibrutinib in treating paraneoplastic pemphigus relate bronchiolitis obliterans concurrent with CLL. Frontiers in Medicine, 0, 10, .	d	2.6	0
160	Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. Journal of C Oncology, 2023, 41, 1820-1824.	linical	1.6	1
161	Recent advances in graft-versus-host disease. Faculty Reviews, 0, 12, .		3.9	0
162	Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell following posttransplant cyclophosphamide. JCI Insight, 2023, 8, .	lymphopoiesis	5.0	1

#	Article	IF	CITATIONS
163	Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease. Bone Marrow Transplantation, 2023, 58, 924-935.	2.4	3
164	The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal:, 2023, 24, 216-220.	0.1	1
165	Pulmonary and Critical Care Considerations in Pediatric Hematopoietic Stem Cell Transplantation Patient. , 2023, , 403-425.		0
166	Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood, 2023, 142, 477-492.	1.4	7
167	Complex interactions of cellular players in chronic Graft-versus-Host Disease. Frontiers in Immunology, 0, 14, .	4.8	2
168	AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunology Research, 2023, 11, 1222-1236.	3.4	1
169	Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death. Journal of Clinical Investigation, 2023, 133, .	8.2	1
170	Murine models of graft versus host disease (GVHD): Focus on ocular GVHD. Ocular Surface, 2023, 30, 179-186.	4.4	1
171	CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice. Journal of Neuroinflammation, 2023, 20, .	7.2	0
172	Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions. Blood Advances, 2024, 8, 667-680.	5.2	0
173	Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab. Transplantation and Cellular Therapy, 2024, 30, 518.e1-518.e13.	1.2	0